TRANSVAC: new vaccines faster
Welcome to TRANSVAC, a collaborative infrastructure project funded under the European Commission’s (EC) 7th Framework Programme (FP7). The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance European research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe.
In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On this website you can find out about how to benefit from TRANSVAC’s portfolio of activities, learn how to apply for access to the TRANSVAC’s high-quality Infrastructure Free Services and Paid Services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is done by the European Vaccine Development Stakeholder Working Groups.
MultiMalVax call for the conduct of a vaccine clinical trial to evaluate the mosquito-stage component of this multi-stage malaria vaccine.
The MultiMalVax CALL is for a suitable European clinical trial site for the conduct of a phase I clinical trial to assess the safety, immunogenicity and ex-vivo efficacy of simian adenovirus (ChAd63) and Modified Vaccinia Ankara (MVA) vectors expressing mosquito stage Plasmodium falciparum antigens. This clinical trial will start in January 2015, enrol 24 volunteers, and should be conducted within 12 months. University of Oxford will act as sponsor of the clinical trial.